Skip to main content

Table 1 Patient demographics at baseline: safety population

From: A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting β2-adrenergic agonist, in asthma; a Phase II, randomized study

 

Patients (N = 62)

Age, mean no. years (SD)

40.9 (11.2)

Male gender, n (%)

40 (64.5)

Race, n (%)

 

  White

58 (93.5)

  Other

4 (6.5)

Cigarette smoking status, n (%)

 

  Former smoker

21 (33.9)

  Never smoked

41 (66.1)

Smoking history, mean no. pack-years (SD)

4.6 (3.3)

Asthma duration, mean no. years (SD)

25.5 (13.2)

Asthma severity, n (%)

 

  60% ≤ FEV1 < 80% of predicted

46 (74.2)

  FEV1 ≥80% of predicted

16 (25.8)

Bronchial reversibilitya, mean % (SD)

21.3 (8.2)

FEV1 absolute reversibilityb, mean L (SD)

0.568 (0.261)

  1. acalculated as 100 x (FEV1 [post-bronchodilator] – FEV1 [pre-bronchodilator]/FEV1 [pre-bronchodilator]); bcalculated as FEV1 (post-bronchodilator) – FEV1 (pre-bronchodilator).
  2. FEV1, forced expiratory volume in 1 s; SD, standard deviation.